• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Neuro-Oncology >IMMU-06. PEMBROLIZUMAB AS SALVAGE TREATMENT IN CHILDREN WITH RECURRENT DIFFUSE MIDLINE GLIOMA: REPORT OF THREE CASES
【2h】

IMMU-06. PEMBROLIZUMAB AS SALVAGE TREATMENT IN CHILDREN WITH RECURRENT DIFFUSE MIDLINE GLIOMA: REPORT OF THREE CASES

机译：IMMU-06。 Pembrolizumab作为复发性弥漫性中线胶质瘤患儿的救治：3例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diffuse midline glioma including diffuse intrinsic pontine glioma is a high grade, infiltrative and very poor prognosis primary pediatric brain tumor, which constitutes 20% within children population. Only radiation therapy was considered a standard treatment until now. Recently, immune checkpoint inhibitor brought us hope as treatment for advanced solid tumor, such as metastasis melanoma. There was only one published report for Pembolizumab, a monoclonal antibody against programmed death-1(PD-1), used in primary brain tumor which showed ineffective results. Other trials related to Pembrolizumab use in glioblastoma are still undergoing. In our institution, there were three children treated with Pembrolizumab after recurrent of diffuse midline glioma, and we collected medical records from these patients to summarize treatment results, complications, and comparison with previous study. The median overall survival from using of Pembrolizumab was 2.47 months. Numbers of cycle of Pembrolizumab were between 1-4 in these patients. One of these children developed moderate hypersensitivity pneumonitis which suspected as adverse effect of Pembrolizumab. All children developed disease progression and no benefits of survival were observed. Because of our number of case was limited, the effectiveness of Pembrolizumab still need more trials and selecting appropriate patients is important in clinical practice.
机译：弥漫性中线神经胶质瘤包括弥漫性桥脑神经胶质瘤是一种高度，浸润性和预后很差的原发性小儿脑肿瘤，占儿童人口的20％。迄今为止，仅放射疗法被认为是标准疗法。最近，免疫检查点抑制剂给我们带来了希望，用于治疗晚期实体瘤，例如转移性黑色素瘤。关于原发性脑肿瘤的一种针对程序性死亡1（PD-1）的单克隆抗体Pembolizumab的公开报道只有一个，其结果无效。与在胶质母细胞瘤中使用派姆单抗有关的其他试验仍在进行中。在我们的机构中​​，有3名儿童在中线弥漫性神经胶质瘤复发后接受了Pembrolizumab治疗，我们收集了这些患者的病历，以总结治疗结果，并发症并与以前的研究进行比较。使用派姆单抗的中位总生存期为2.47个月。这些患者中Pembrolizumab的周期数在1-4之间。这些孩子之一发展为中度超敏性肺炎，怀疑是派姆单抗的不良反应。所有儿童均进展为疾病，未观察到生存益处。由于我们的病例数有限，因此仍然需要进行更多的试验来验证派姆单抗的有效性，并且在临床实践中选择合适的患者非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号